Category survey

Identification of Parkinson’s disease genes in Queensland families showing patterns of Mendelian inheritance.

Identification of Parkinson’s disease genes in Queensland families showing patterns of Mendelian inheritance. Investments < €500k Australia 2016

Investigating the cause and consequences of iron deposition in Parkinson’s disease

Investigating the cause and consequences of iron deposition in Parkinson’s disease Investments < €500k Australia 2016

RNA-based Expanded Repeat Pathogenic Pathway in Neurodegenerative Diseases

RNA-based Expanded Repeat Pathogenic Pathway in Neurodegenerative Diseases Investments < €500k Australia 2016

Understanding the role of TDP-43 in motor neuron disease.

Understanding the role of TDP-43 in motor neuron disease. Investments < €500k Australia 2016

Bioenergetic deficit in neurodegeneration: studies in motor neuron disease (MND)

Bioenergetic deficit in neurodegeneration: studies in motor neuron disease (MND) Investments < €500k Australia 2016

Targeting autophagy to improve protein metabolism in ALS

Targeting autophagy to improve protein metabolism in ALS Investments < €500k Australia 2016

Axon degeneration and axon protection in CNS disease and injury

Axon degeneration and axon protection in CNS disease and injury Investments < €500k Australia 2016

Improving a new form of deep brain stimulation to treat gait and balance disturbance in Parkinson’s disease

Improving a new form of deep brain stimulation to treat gait and balance disturbance in Parkinson’s disease Investments < €500k Australia 2016

The functional interplay between alpha synuclein and synaptophysin in synaptic vesicle recycling

The functional interplay between alpha synuclein and synaptophysin in synaptic vesicle recycling Investments < €500k Australia 2016

Maintaining mitochondrial health in Parkinson’s disease: The role of PINK1 and Parkin

Maintaining mitochondrial health in Parkinson’s disease: The role of PINK1 and Parkin Investments < €500k Australia 2016

Defining the machinery for mitochondrial turnover governed by the Parkinsons Disease proteins PINK1 and Parkin

Defining the machinery for mitochondrial turnover governed by the Parkinsons Disease proteins PINK1 and Parkin Investments < €500k Australia 2016

Complement activation as a therapeutic target and clinical biomarker for Parkinson’s disease

Complement activation as a therapeutic target and clinical biomarker for Parkinson’s disease Investments < €500k Australia 2016

The role of long noncoding RNAs in Parkinsons Disease

The role of long noncoding RNAs in Parkinsons Disease Investments < €500k Australia 2016

How do small extracellular vesicles contribute to the development of prion disease

How do small extracellular vesicles contribute to the development of prion disease Investments < €500k Australia 2016

Prion-like behaviour in immunity: super-sized signalling platforms?

Prion-like behaviour in immunity: super-sized signalling platforms? Investments < €500k Australia 2016

Growth hormone ameliorates ageing dementia

Growth hormone ameliorates ageing dementia Investments < €500k Australia 2016

Structure and activity determination of membrane-active peptides

Structure and activity determination of membrane-active peptides Investments < €500k Australia 2016

New Directions in Bayesian Statistics: formulation, computation and application to exemplar challenges

New Directions in Bayesian Statistics: formulation, computation and application to exemplar challenges Investments < €500k Australia 2016

Defining systems that clear dangerous misfolded proteins from body fluids

Defining systems that clear dangerous misfolded proteins from body fluids Investments < €500k Australia 2016

Microfluidic technology to help understand physical damage to brain cells

Microfluidic technology to help understand physical damage to brain cells Investments < €500k Australia 2016

Financial Decision making in Late Adulthood

Financial Decision making in Late Adulthood Investments < €500k Australia 2016

The effect of hypochlorite on the toxicity and clearance of the Alzheimer’s disease-associated amyloid beta peptide

The effect of hypochlorite on the toxicity and clearance of the Alzheimer’s disease-associated amyloid beta peptide Investments < €500k Australia 2016

Role of IRAP in Alzheimer’s Disease

Role of IRAP in Alzheimer’s Disease Investments < €500k Australia 2016

Membrane trafficking in Alzheimer’s disease

Membrane trafficking in Alzheimer’s disease Investments < €500k Australia 2016

The genetic and environmental determinants of amyloid deposition in older individuals: an amyloid imaging study using the twin design

The genetic and environmental determinants of amyloid deposition in older individuals: an amyloid imaging study using the twin design Investments < €500k Australia 2016

Amyloid Precursor Protein Signalosome: directing Abeta production in Alzheimer’s disease

Amyloid Precursor Protein Signalosome: directing Abeta production in Alzheimer’s disease Investments < €500k Australia 2016

AIBL III – Efficient identification of preclinical AD

AIBL III – Efficient identification of preclinical AD Investments < €500k Australia 2016

Pathophysiology of ALS

Pathophysiology of ALS Investments < €500k Australia 2016

Cellular transport dysfunction and motor neuron disease

Cellular transport dysfunction and motor neuron disease Investments < €500k Australia 2016

Harnessing the consequences of impaired mitochondrial energy metabolism to treat the symptoms of age-related neuronal decline

Harnessing the consequences of impaired mitochondrial energy metabolism to treat the symptoms of age-related neuronal decline Investments < €500k Australia 2016

The regulation of iron transport in Parkinson’s disease

The regulation of iron transport in Parkinson’s disease Investments < €500k Australia 2016

Closed-loop deep brain stimulation: Optimising treatment of Parkinsons disease using adaptive stimulation

Closed-loop deep brain stimulation: Optimising treatment of Parkinsons disease using adaptive stimulation Investments < €500k Australia 2016

Cognitive decline in diabetes

Cognitive decline in diabetes Investments < €500k Australia 2016

Restoration of cognitive deficits induced by diabetes through the modulation of cerebrovascular integrity

Restoration of cognitive deficits induced by diabetes through the modulation of cerebrovascular integrity Investments < €500k Australia 2016

Freezing of Gait in Parkinson’s Disease

Freezing of Gait in Parkinson’s Disease Investments < €500k Australia 2016

Optimising Health of the Ageing Brain

Optimising Health of the Ageing Brain Investments < €500k Australia 2016

Towards a unifying theory of Parkinsons disease: Investigation of the biochemical and genetic role of Rab GTPases

Towards a unifying theory of Parkinsons disease: Investigation of the biochemical and genetic role of Rab GTPases Investments > €500k Germany|United Kingdom Parkinson’s disease & PD-related disorders 2016

Decoding Presymptomatic white matter changes in Huntington Disease (WIN-HD)

Decoding Presymptomatic white matter changes in Huntington Disease (WIN-HD) Investments > €500k France|United Kingdom Huntington’s disease 2016

GWAS in AD: focus on microRNA

GWAS in AD: focus on microRNA Investments > €500k Canada|France Alzheimer’s disease & other dementias 2016

RHAPSODY: Research to assess Polices and Strategies for Dementia in Young

CrossSeeds: Mechanisms of pathogenic protein cross-seeding in neurodegenerative disorders

InCure: Innate Immune Activation in Neurodegenerative Disease

CeBioND: Cellular Bioenergetics in Neurodegenerative Diseases: A system based pathway and target analysis

DAMNDPATHS: Elucidation of common transcriptional targets in vulnerable DopAmine, MotorNeuron and frontotemporal Dementia disease PATHwayS

Fly-SMALS: Common RNA-dependent pathways for motor neuron degeneration in spinal muscular atrophy and amyotrophic lateral sclerosis

NeuroGeM: Identification of genes that modulate the severity of all neurodegenerative diseases

NeuTARGETs: Targeting the propagation of pathogenic protein assemblies in neurodegenerative disease

PrPC&PDK1: The PrPC / PDK1 / TACE signaling axis at the cross-road of several aggregate-prone protein-associated neurodegenerative diseases

SynSpread: Role and mechanism of alpha-synuclein and ataxin-3 spreading in Parkinson and Machado-Joseph diseases

SynSpread: Role and mechanism of alpha-synuclein and ataxin-3 spreading in Parkinson and Machado-Joseph diseases Investments > €500k|JPND Projects France|JPND|Luxembourg|Portugal Parkinson’s disease & PD-related disorders|Spinocerebellar ataxia (SCA) 2016

GBA-PARK: GBA1 mutations in Parkinson disease: clinical and biochemical prodrome, risk profile and pathogenetic modelling for therapeutic intervention

GBA-PARK: GBA1 mutations in Parkinson disease: clinical and biochemical prodrome, risk profile and pathogenetic modelling for therapeutic intervention Investments > €500k|JPND Projects Canada|Germany|Italy|JPND|United Kingdom Parkinson’s disease & PD-related disorders 2016